10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

10x Genomics, Inc.

Cells are the basic unit of life. They power everything we do, and unlocking their secrets is the key to advancing our knowledge of every facet of biology, from development to disease. Our single cell, spatial, and in situ tools enable researchers to answer pressing questions about cells and their functional contributions to oncology, immunology, neuroscience, and much more—as evidenced by more than 5,500 publications citing our technology. We are dedicated to building the best products, delivering the best customer experience, and creating the best team to fuel new scientific discovery, no matter how challenging. And we won’t stop until all of the cells’ secrets are revealed.

10x Genomics

 #Singlecellspatial lets researchers like Dr. Nick Banovich take their research to the next level by offering gross tissue morphology and single-molecule RNA transcript detection at subcellular resolution on a single section. Hear why he was excited to get his hands on Xenium #InSitu in a quick clip below, then watch the full webinar for more! https://lnkd.in/gurVFX-r

We just wrapped up an amazing, empowering week in Palm Springs with our global commercial team! 🌴🎉 The week unfolded with a focus on innovation and professional development featuring keynote speakers and breakout sessions. Did we mention we also had a ton of fun?! We had an array of team-building activities, from early morning sessions of pickleball and yoga, to carnival booth games, to an "Old Hollywood''-themed awards celebration and dinner. A HUGE thanks to our amazing commercial team who brought collaborative energy, shared powerful insights, and strengthened professional relationships. 🙌 

Hippos eat more than 80 lbs of food a day to support their massive size. Organs use the Hippo pathway—which controls organ size by regulating cell proliferation and apoptosis. #Cancer often takes advantage of the Hippo pathway to boost tumor growth, but therapeutically targeting it is challenging. Check out this study to see how Genentech researchers used #singlecell methods to measure the efficacy of their small molecule inhibitor candidate! 

Heart defects are the leading cause of fetal death, but, historically, research on this important subject has been difficult for a number of reasons, including the inaccessibility of human embryonic samples and the limitations of in vitro models. However, in honor of #AmericanHeartMonth, we’re highlighting a recent paper that uncovered new insights into underlying defects in the developing human heart, using our #singlecell Flex assay to generate compartment-specific, in vivo–like gene expression profiles. Read the paper!

What do mini-kidneys, tiny tumors, and little livers have in common? They were highlighted in one of our top blogs from 2023! Read the blog to learn how scientists are using #organoid models and high-resolution #singlecell analysis to identify druggable disease pathways, screen drugs, model drug metabolism, and explore patient-specific therapeutic responses! 

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover	0.94 -	1.18 25.19%	0.41 65.52%	0.32 20.76%	0.48 49.71%	0.50 4.25%	0.64 27.74%
cash conversion cycle	47.59 -	70.93 49.04%	62.94 11.26%	220.17 249.79%	273.38 24.17%	255.66 6.48%	168.78 33.98%
cash per share	0.62 -	0.79 27.14%	10.85 1,282.03%	6.56 39.54%	5.32 18.85%	3.78 29.06%	3.32 12.15%
company equity multiplier	-0.67 -	-0.57 15.91%	1.44 355.25%	1.26 12.82%	1.25 0.90%	1.28 2.48%	1.30 1.99%
days of inventory outstanding	167.22 -	109.14 34.73%	91.32 16.33%	187.03 104.80%	295.41 57.95%	247.49 16.22%	128.47 48.09%
days of payables outstanding	188.13 -	111.97 40.49%	77.91 30.41%	29.40 62.27%	85.48 190.77%	65.49 23.39%	27.43 58.11%
days of sales outstanding	68.50 -	73.76 7.67%	49.54 32.84%	62.54 26.26%	63.44 1.44%	73.66 16.10%	67.74 8.03%
dividend yield
ebit per revenue	-0.26 -	-0.76 192.86%	-0.12 84.38%	-0.29 141.50%	-0.11 62.22%	-0.33 201.47%	-0.33 0.32%
ebt per ebit	1.02 -	1.01 0.51%	1.07 5.20%	6.26 486.80%	1.02 83.79%	0.96 5.00%	1.23 27.77%
effective tax rate	-0.00 -	-0.00 30.92%	-0.01 807.55%	-0.02 119.87%	-0.08 443.37%	-0.02 70.36%	-0.03 2.39%
enterprise value multiple	-297.29 -	-330.05 11.02%	-97.77 70.38%	-166.42 70.22%	-297.74 78.91%	-24.92 91.63%	-39.76 59.57%
fixed asset turnover	10.26 -	13.15 28.10%	5.04 61.70%	2.49 50.48%	2.13 14.65%	1.44 32.47%	1.79 24.77%
free cash flow per share	-0.19 -	-1.00 437.58%	-0.21 79.23%	-2.53 1,116.80%	-1.11 56.13%	-1.45 30.59%	-0.55 61.94%
gross profit margin	0.85 -	0.80 5.56%	0.75 6.51%	0.80 6.99%	0.85 5.54%	0.77 9.67%	0.66 13.74%
interest coverage	-22.66 -	-45.98 102.93%	-9.44 79.47%	-50.73 437.27%	-61.10 20.45%	-352.82 477.45%	-6.12K 1,633.79%
inventory turnover	2.18 -	3.34 53.22%	4.00 19.51%	1.95 51.17%	1.24 36.69%	1.47 19.36%	2.84 92.65%
long term debt to capitalization	-0.06 -	-0.13 119.64%	0.05 134.41%	0.07 58.90%	0.09 19.91%	0.10 12.41%	0.10 5.25%
net income per ebt	1.00 -	1.00 0.03%	1.01 0.62%	1.02 0.84%	1.08 6.74%	1.02 5.45%	1.03 0.06%
net profit margin	-0.26 -	-0.77 191.28%	-0.13 83.47%	-1.82 1,328.96%	-0.12 93.46%	-0.32 170.80%	-0.41 28.26%
operating cash flow per share	-0.14 -	-0.92 567.67%	0.89 196.09%	-2.15 343.19%	-0.19 91.01%	-0.30 52.39%	-0.13 56.06%
operating cycle	235.72 -	182.90 22.41%	140.86 22.99%	249.57 77.18%	358.86 43.79%	321.15 10.51%	196.21 38.90%
operating profit margin	-0.26 -	-0.76 192.86%	-0.12 84.38%	-0.29 141.50%	-0.11 62.22%	-0.33 201.47%	-0.33 0.32%
payables turnover	1.94 -	3.26 68.03%	4.68 43.71%	12.42 165.03%	4.27 65.61%	5.57 30.53%	13.31 138.73%
pretax profit margin	-0.26 -	-0.77 191.38%	-0.13 83.57%	-1.79 1,317.11%	-0.11 93.88%	-0.31 186.40%	-0.40 28.19%
price fair value	-36.33 -	-19.88 45.30%	7.10 135.70%	19.38 173.13%	20.11 3.74%	5.15 74.39%	8.85 71.82%
receivables turnover	5.33 -	4.95 7.12%	7.37 48.90%	5.84 20.80%	5.75 1.42%	4.96 13.87%	5.39 8.73%
return on assets	-0.25 -	-0.90 264.66%	-0.05 94.30%	-0.58 1,032.30%	-0.06 90.21%	-0.16 182.30%	-0.26 63.84%
return on capital employed	-0.34 -	-1.20 250.53%	-0.05 95.55%	-0.11 96.41%	-0.06 44.62%	-0.19 221.09%	-0.24 28.81%
return on equity	0.17 -	0.51 206.62%	-0.07 114.55%	-0.73 887.12%	-0.07 90.30%	-0.21 189.29%	-0.34 67.09%
total debt to capitalization	-0.10 -	-0.16 50.56%	0.07 142.37%	0.08 18.84%	0.09 16.06%	0.11 15.92%	0.11 7.93%

COM:10XGENOMICS

10x Genomics, Inc.

Last Close

13.29

22/11 21:00

Market Cap

1.88B

Beta: -

Volume Today

4.50M

Avg: -

Preview